Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.45 |
| ▸ | KAT7 | O95251 | 18/20 | 0.43 |
| ▸ | KAT6A | Q92794 | 18/20 | 0.43 |
| ▸ | KAT6B | Q8WYB5 | 11/20 | 0.43 |
| ▸ | KAT5 | Q92993 | 11/20 | 0.43 |
| ▸ | KAT8 | Q9H7Z6 | 11/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30019841 | 1.00 | PDE4B (0.45) | PDE4BKAT7KAT6AKAT6BKAT5 | |
| SCHEMBL30020086 | 0.79 | KAT7 (0.39) | PDE4BKAT7KAT6AKAT6BKAT5 | |
| SCHEMBL30020281 | 0.78 | KAT7 (0.70) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL25561771 | 0.78 | KAT7 (0.70) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL22802429 | 0.78 | KAT7 (0.63) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL25564680 | 0.77 | KAT7 (0.46) | PDE4BKAT7KAT6AKAT6BKAT5 | |
| SCHEMBL27176108 | 0.77 | KAT7 (0.38) | PDE4BKAT7KAT6AKAT6BKAT5 | |
| SCHEMBL27205105 | 0.76 | KAT7 (0.39) | KAT7KAT6AKAT6BKAT5KAT8 | |
| SCHEMBL25564684 | 0.76 | IDO1 (0.43) | PDE4B | |
| SCHEMBL29189486 | 0.75 | PDE4B (0.46) | PDE4BKAT7KAT6AKAT6BKAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254139-A1 | FUSED ISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | AURIGENE ONCOLOGY LTD (IN) | 2024-08-01 | — | — | US | disclosed |
| CN-117881677-A | Fused isoxazolyl compounds as KAT6Aw inhibitors | 奥瑞基尼肿瘤有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4341259-A1 | FUSED ISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | Aurigene Oncology Limited (IN) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023088233-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITORS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254139-A1 | FUSED ISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS | KAT6A, KAT6B, KAT2A | PDE4B 4248/4885KAT7 4/4885KAT6A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.